Faculty from the Department of Pharmacology and Physiology are frequently highlighted in local and national news media.
View examples of recent news coverage below.
βChemo Brainβ Can Impact Quality of Life Long After Treatment
ΘνΓΓΙη pain researcher Daniela Salvemini joined FOX2 Now to discuss βchemo brain.β Lingering symptoms can dramatically impact patientsβ quality of life long after they have completed their cancer treatments.
Pelaez to Join Department
![Headshot of Juliana Perez Headshot of Juliana Perez](/medicine/medical-education/graduate-programs/pharmacology-physiology/news/-img/navia.jpg)
Juliana M. Navia Pelaez, Ph.D., will join the Department of Pharmacology and Physiology, on Feb. 1, 2024, as assistant professor (TT).
Navia Pelaez, Ph.D, completed her graduate studies in vascular biology at UFMG, Brazil, focusing on cellular responses to oxidized lipids. Subsequently, she pursued postdoctoral training in pain and metabolism at the University of California, San Diego, under the dual mentorship of Tony Yaksh (vice chair for research in Anesthesiology and Distinguished Professor in Anesthesiology and Pharmacology) and Yury Miller (M.D., Ph.D; professor of medicine, Division of Endocrinology and Metabolism). As a postdoc, her findings, which revealed increased lipid rafts and intracellular lipid storage in microglia and neurons, contributed to the growing knowledge linking dysregulated lipid metabolism to hypersensitivity and pain states.
Now, she is set to lead a new laboratory at ΘνΓΓΙη in the Department of Pharmacology and Physiology, dedicated to understanding how lipid metabolism influences pain states and susceptibility to chronic pain. Her research will primarily investigate immuno-metabolic changes and the related transcriptional regulation underlying chronic pain development. Leveraging diverse animal models of chronic pain and advanced omics and biochemistry tools, her lab will explore neuroimmune interactions, cellular reprogramming, and metabolic shifts across various cell types involved in nociceptive pathways, particularly macrophages and microglia. The lab aims to discover early pain biomarkers and uncover new pathways and potential therapeutic targets for treating various chronic pain conditions.
Cifarelli Receives President Research Fund Award
Vincenza Cifarelli, Ph.D., assistant professor in the Department of Pharmacology and Physiology, has been awarded a President Research Fund of $50,000. The grant titled, "Determining the role of a novel E3 ligase Ube4A in intestinal function and IBD" will allow Cifarelli and her colleague Anutosh Chakraborty, Ph.D., also in the Department of Pharmacology and Physiology, to decipher mechanisms by which the Ube4A protein regulates intestinal function and disease. The project will utilize new mouse models and various cutting-edge tools to define novel mechanisms that cause intestinal diseases and may offer new therapeutic strategies for the treatment of inflammatory bowel disease and colitis.
Samson Named New President-Elect of the American Physiological Society
Willis (Rick) Samson, Ph.D., was elected President of the American Physiological Society. He will serve as President-Elect until April 2023. He will then take over as president of the society. Dr. Samson has been active in APS since he was a trainee and previously served the society as a member of council and as editor-in-chief of AJP-Regu, among many other service roles. The APS has over 10,000 members worldwide. This is a huge honor! Congratulations Dr. Samson!
Salvemini Appointed Associate Editor
Daniela Salvemini, Ph.D., was appointed an associate editor for American Chemistry Society Pharmacology & Translational Science.
Squillace Wins Outstanding Poster Finalist
Silvia Squillace, Ph.D., a postdoctorate fellow in Daniela Salvemini's lab, presented a Data Blitz and a Poster entitled "Activation of S1PR1 Signaling in the CNS drives Cisplatin-Induced Cognitive Impairment," which was awarded as "Outstanding Poster Finalist" during the 54th Winter Conference of Brain Research in Snowmass, Colorado.
Three New PIs to Join Department Faculty in February of 2022
The Department of Pharmacology and Physiology is excited to announce the recruitment of three outstanding PIs that will be joining the department in February 2022 as part of our ongoing cluster hiring to grow pain, neuroscience and metabolism research at ΘνΓΓΙη. These new faculty are:
![Vincenza Cifarelli, Ph.D Vincenza Cifarelli, Ph.D](/medicine/medical-education/graduate-programs/pharmacology-physiology/news/-img/vincenzacifarellifinal.jpg)
Vincenza Cifarelli, Ph.D., will be joining us from Washington University in Saint Louis as an assistant professor. She will pursue her work on the contribution of the endothelial dysfunction in the development of the immuno-metabolic abnormalities associated with obesity and the metabolic syndrome. Her interdisciplinary research program investigates how blood and lymphatic vasculature regulate the gut-adipose tissue axis. Her studies aim to provide plausible original therapeutic strategy for treating obesity by targeting the intestinal vascular and lymphatic endothelium, which recent studies indicate to be an important regulator of body fat distribution, visceral fat deposition and inflammation during diet-induced obesity.
![Aubin Moutal, Ph.D Aubin Moutal, Ph.D](/medicine/medical-education/graduate-programs/pharmacology-physiology/news/-img/moutalaubin-final.jpg)
![Liberty Francois-Moutal, Ph.D. Headshot of Liberty Francois-Moutal, Ph.D.](/medicine/medical-education/graduate-programs/pharmacology-physiology/news/-img/moutallibertyfinal.jpg)
Liberty Francois-Moutal, Ph.D., will be joining us from University of Arizona, Tucson as an assistant research professor. She will focus on studying the synaptic delivery of mRNA in neurodegeneration and painful neuropathies. With her expertise in biochemistry, biophysical characterization of protein interactions with biologically active molecules, as well as drug design approaches, she aims to characterize and target interactions relevant to RNA transport as well as foster new collaborations.
With $5.3 Million from NIH, DOD, ΘνΓΓΙη and University of Maryland Pain Researchers Set Their Sights on Migraine Relief
Thanks to $5.3 million from the Department of Defense (DOD) and the National Institutes of Health (NIH), ΘνΓΓΙη pain researcher Daniela Salvemini, Ph.D., and colleagues from the University of Maryland School of Dentistry (UMSOD) are in pursuit of a new way to treat migraine pain, a complex and painful disorder that affects over 30 million people in the U.S., including children as young as 5 years old.
Meet A ΘνΓΓΙη Researcher: Koyal Garg, Ph.D.
Koyal Garg, Ph.D., is an associate professor of Biomedical Engineering and has a secondary appointment in the SOM-Pharmacology and Physiology at ΘνΓΓΙη. Gargβs research focuses on the enhancement of skeletal muscle regeneration and function following injury, disease, and aging. In her own words, Garg shares why she does what she does, her goals for her research and what it's like working at ΘνΓΓΙη.
View More about Koyal Garg, Ph.D.
Galaxy@ΘνΓΓΙη Launched to Public
Galaxy@ΘνΓΓΙη, maintained by the Department of Pharmacology and Physiology, is now one of 134 publicly accessible Galaxy-based bioinformatics servers in the world. Learn more at .
Pharm/Phys Faculty Honored by the Selection of Their Article as "Featured Article of the Week" in the Official Journal of The Endocrinology Society
Willis K Samson, Daniela Salvemini, Gina L C Yosten, Overcoming Stress, Hunger, and Pain: Cocaine- and Amphetamine-Regulated Transcript Peptideβs Promise, Endocrinology, Volume 162, Issue 8, August 2021, bqab108.
Grant Kolar, Ph.D. Publishes Blog with AWS
Patents by Inventors Drs. Salvemini, Samson, Yeung, & Yosten
Patent Title: Methods of treating pain using anti-GPR160 antibodies
Patent number: 10851378
Abstract: The disclosure provides methods and compositions for inhibiting pain by
administering a GPR160 antagonist to a subject in need thereof. Also provided are
methods of using GPR160 antagonists in combination with other pain therapies.
Date of Patent: December 1, 2020
Inventors: Daniela Salvemini, Gina L. C. Yosten, Willis K. Samson
Patent Title: Compositions and methods for diagnosing and treating endometriosis-related
infertility
Patent number: 10877045
Abstract: Disclosed are methods of diagnosing and treating endometriosis, and in particular,
endometriosis-associated infertility.
Date of Patent: December 29, 2020
Inventors: Patrick Yeung, Jr., Daniela Salvemini
Willis K. βRickβ Samson, Ph.D., Receives Two Honors
On July 16, Rick Samson, Ph.D., was installed as the 33rd president of the Society
for the Study of Ingestive Behaviors (SSIB), an international organization committed
to advancing scientific research on food and fluid intake and its associated biological,
psychological and social processes.
In August, Samson will be honored as a distinguished member of the International Regulatory
Peptide Society (regpep.org). His acceptance presentation will be βChallenges for
the Field: Peptides as Therapeutics: Orphan G Protein-Coupled Receptor β Ligand Matching
is Just the Beginning.β He will be highlighting results of a fruitful, 16-year-long
collaboration with Dr. Gina L.C. Yosten, an associate professor in the department.
Daniela Salvemini, Ph.D. Awarded Department of Defense Grant
Daniela Salvemini, Ph.D. was awarded a grant entitled βSphingosine-1-Phosphate Receptor
Subtype 1: A Novel Target in the Treatment of Chronic Migraineβ from the Department
of Defense. The funding period is July 1, 2021-June 30, 2025 and the funded amount
$1,280,322.
Migraine and post-traumatic headache (PTH) are widely prevalent disabling disorders.
They are far more prevalent in military service personnel, as they are a common feature
of mild traumatic brain injury, where a migraine predisposition is more likely to
produce adverse outcomes. Despite their high prevalence there are major gaps in our
understanding of their pathobiology. Moreover, our ability to treat the more frequent
and chronically disabling forms of migraine and PTH are limited. The objectives of
our proposal are to understand the roles of sphingolipids, and in particular S1P,
in nociceptive mechanisms involved in the pathobiology of migraine-like headaches
and the potential use of S1PR1 antagonists in these conditions.
John K. Walker, Ph.D., Elected as Senior Member of the 2021 Class of National Academy of Inventors - February 2021
John K. Walker, Ph.D., was elected as a NAI Senior member of the National Academy of Inventors in recognition of his dedication to invention and innovative work in his field. He is named an inventor on 13 issued U.S. patents, and is a co-founder of two companies (Pelagos Pharmaceuticals and Myonid Therapeutics) working in the drug discovery field, developing technologies partially identified in his lab.
The Future of Neuroscience, for the Service of Humanity - Fall 2020
Understanding how to treat diseases of the brain and nervous system, like ALS, Alzheimerβs disease, dementia, and pain, requires more than just research, discoveries, and development in one scientific discipline, but rather a multidisciplinary approach that brings together several experts across disciplines, all of whom are committed to better understanding how neuroscience works.
Gina Yosten Awarded Grant from the Foundation for Prader-Willi Research - Spring 2021
Gina Yosten, Ph.D., was awarded a grant from the Foundation for Prader-Willi Research in February in support of her proposal entitled, βOrphan GPCRs and the Neurobiology of Hyperphagia in Prader Willi Syndrome: Role of GPR160." The goal of Yosten's proposal is to evaluate the potential role of a molecule called cocaine- and amphetamine-regulated transcript, or CART, in appetite regulation using a rat model of Prader-Willi Syndrome.
Daniela Salvemini Accepts Chair position, Department of Pharmacology and Physiology - March 2021
Daniela Salvemini, Ph.D., has accepted the position of Chair, Department of Pharmacology and Physiology, effective March 1, 2021. Dr. Salvemini also holds the William Beaumont Professor and Chair. Dr. Salvemini received her Ph.D. from London University. She completed her postdoctoral study at The William Harvey Research Institute at Saint Bartholomewβs Hospital Medical College and in the Department of Molecular Pharmacology at Monsanto Corporate Research.
New Book by Former ΘνΓΓΙη Pharmacology and Physiology Chair Thomas C. Westfall Details History of Department - April 2021
Thomas C. Westfall, Ph.D., former William Beaumont Professor and Chair of the Department of Pharmacology (1979-1990) as well as the Department of Pharmacology and Physiology (1990-2013) at the ΘνΓΓΙη School of Medicine, recently published a book, entitled: "The History of Pharmacology and Physiology at ΘνΓΓΙη School of Medicine."
Dr. Gina L.C. Yosten Selected the Next Editor-in-Chief of the American Journal of Physiology - Summer 2020
After a lengthy international search the publications committee and executive council of the American Physiological Society have chosen Dr. Gina L.C. Yosten, assistant professor of pharmacology and physiology at the ΘνΓΓΙη School of Medicine, to be the next editor-in-chief of the American Journal of Physiology (Regulatory, Integrative and Comparative Physiology).
ΘνΓΓΙηβs Daniela Salvemini Honored for Pain Discoveries - Winter 2020
Researcher Daniela Salvemini, Ph.D., professor of pharmacology and physiology at Saint Louis University, has been named a fellow of the National Academy of Inventors (NAI) for her contributions toward understanding and finding better treatments for pain. Fellows of the NAI are academic inventors who have made a significant difference in the quality of life in society.
Daniela Salvemini, Ph.D., Awarded the 2020 Pharmacia-ASPET Award for Experimental Therapeutics from ASPET - April 2020
ASPET is pleased to award Dr. Daniela Salvemini from ΘνΓΓΙη School of Medicine the 2020 Pharmacia-ASPET Award for Experimental Therapeutics. The Pharmacia-ASPET Award for Experimental Therapeutics recognizes and stimulates outstanding research in pharmacology and experimental therapeutics, basic laboratory or clinical research that has had, or potentially will have, a major impact on the pharmacological treatment of disease.